Tìm kiếm thay thế:
harm » farm (Mở rộng tìm kiếm)
revolves. » resolves. (Mở rộng tìm kiếm), resolved. (Mở rộng tìm kiếm), evolved. (Mở rộng tìm kiếm)
resolveddddds. » resolvedddddds. (Mở rộng tìm kiếm)
resolve. » resolved. (Mở rộng tìm kiếm)
Đang hiển thị 1 - 20 kết quả của 142 cho tìm kiếm 'harm is (((((evolveddss. OR resolveddddds.) OR revolves.) OR involved.) OR involves.) OR resolve.)*', thời gian truy vấn: 0.09s Tinh chỉnh kết quả
  1. 1
    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl

    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl Bằng Elham Mazarei (4508746)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    Claudin-5 is involved in one of the main proteins that control the blood-brain barrier (BBB).

    Claudin-5 is involved in one of the main proteins that control the blood-brain barrier (BBB). Bằng Zhizhong Wang (838758)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    Participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year).

    Participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year). Bằng Olga Amberger (20299807)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    LOESS curves of participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year).

    LOESS curves of participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year). Bằng Olga Amberger (20299807)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  7. 7
    Spatial distribution of overall non-carcinogenic risk (HI) for (a) infants, (b) Children, (c) adult females, and (d) adult males posed by potential harmful substances of groundwater within the Tongde Basin.

    Spatial distribution of overall non-carcinogenic risk (HI) for (a) infants, (b) Children, (c) adult females, and (d) adult males posed by potential harmful substances of groundwate... Bằng Shanhu Xiao (22226759)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  8. 8
    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings.

    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  9. 9
    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis.

    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  10. 10
    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis.

    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  11. 11
    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference.

    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  12. 12
    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis.

    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  13. 13
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  14. 14
    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis.

    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  15. 15
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  16. 16
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  17. 17
    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  18. 18
    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  19. 19
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  20. 20
    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: